Strata Critical Medical (SRTA) Common Equity (2019 - 2026)

Strata Critical Medical (SRTA) has 8 years of Common Equity data on file, last reported at $285.7 million in Q1 2026.

• Quarterly Common Equity rose 30.04% year-over-year to $285.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $285.7 million (up 30.04% YoY) and the FY2025 annual result came in at $279.1 million, up 25.74% from the prior year.
• Common Equity grew to $285.7 million in Q1 2026 per SRTA's latest filing, from $279.1 million in the prior quarter.
• Across five years, Common Equity topped out at $292.3 million in Q2 2022 and bottomed at $219.7 million in Q1 2025.
• The 5-year median for Common Equity is $262.9 million (2023), against an average of $257.1 million.
• The widest annual swing landed in 2022, when Common Equity soared 3557.35%; it then fell 14.64% in 2023.
• Tracing SRTA's Common Equity over 5 years: stood at $274.5 million in 2022, then slipped by 14.64% to $234.3 million in 2023, then slipped by 5.28% to $221.9 million in 2024, then increased by 25.74% to $279.1 million in 2025, then rose by 2.39% to $285.7 million in 2026.
• Per Business Quant, the three latest SRTA Common Equity figures stand at $285.7 million (Q1 2026), $279.1 million (Q4 2025), and $283.0 million (Q3 2025).

Peer Comparison